The company said it had notified the U.S. antitrust watchdog of its intention to divest its experimental inflammatory bowel disease therapy, brazikumab, and its treatment for a type of pancreatic disease, Zenpep. The agency asked the companies for additional information in September that AbbVie said was not unexpected and that the companies were working through the FTC’s requests. …read more
Source:: Yahoo Finance
